The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.
4d
iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between ...
SineuGene Therapeutics receives US FDA’s investigational new drug application clearance for SNUG01 to treat amyotrophic lateral sclerosis: Beijing Thursday, March 27, 2025, 15:0 ...
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024 <li /> Up to $7.5 mil ...
Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief ...
French precision fermentation startup Bon Vivant has rebranded to Verley and rolled out a range of functional animal-free ...
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
CJ BIO's BiomeNrichtm POST M005 is the first Akkermansia muciniphila-based ingredient to receive New Dietary Ingredient ...
As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.
BEIJING, China I March 24, 2025 I SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for ...
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback